ENDOCRINE SYSTEM
Thyroid Scintigraphy
Procedure description:
The procedure is used for differentiation of subacute or painless thyroiditis, and factitious hyperthyroidism from Grave’s disease and other forms of hyperthyroidism.
The procedure is also used for the confirmation of the diagnosis of hyperthyroidism due to Grave’s disease. The procedure is also used for the determination and functional assessment of thyroid nodules. Also, it’s used for the evaluation of congenital hypothyroidism, to confirm or exclude thyroid dysgenesis - ectopia, hyperplasia, and agencies, dyshormonogenesis.
Patient preparation:
Inform the clinic if the patient is on medications such as thyroid hormones or antithyroid drugs.
Inform the clinic if the patient had water-soluble iodinated contrast in the last 4 weeks.
Antithyroid drugs should be withheld for 4 days before the procedure.
Thyroid hormone (FT4) treatment should be stopped for 4-6 weeks.
Thyroid hormone (FT3) treatment should be stopped for 2 weeks.
Parathyroid Scintigraphy
Procedure description:
The procedure provides for the localisation of parathyroid adenomas or parathyroid hyperplasia in patients with hyperparathyroidism, in patients with elevated parathyroid hormone levels in a setting of an elevated serum calcium level.
Localisation of hyper functioning parathyroid tissue (adenomas or hyperplasia, is useful before surgery to help the surgeon localise the lesion, thus shortening the time of the procedure. This provides for a minimally invasive parathyroidectomy, with extremely reduced duration and extent of surgical intervention.
Patient preparation:
No special patient preparation or precautions are necessary. Patient should bring along with recent parathyroid hormone, and serum calcium level results and a letter of referral.
Salivary Gland Scintigraphy
Procedure description:
(Work in progress)
Key patient preparation:
(Work in progress)
Dacryoscintigraphy
Procedure description:
(Work in progress)
Key patient preparation:
(Work in progress)